The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 50)
LRRK2 Biology Consortium, 2017
Promising Outcomes of Original Grant:
Our original project investigated how the LRRK2 mutation, the principal genetic cause of Parkinson's disease (PD), alters brain activity involved in movement control and sleep quality. In line with our original hypothesis, we observed that pre-clinical models with the LRRK2 mutation slept less and had more powerful sleep spindles, a form of brain wave involved ...
Researchers: Stephen L. Cowen, PhD
Target Advancement Awards, 2017
The pathological hallmark of Parkinson's disease (PD) is the widespread accumulation of cellular deposits (Lewy Bodies) comprised of clumps of a misfolded protein called alpha-synuclein. Evidence suggests that misfolded alpha-synuclein can be taken up into healthy neurons where it seeds further clumping of toxic alpha-synuclein. Prevention of the uptake of pathological alpha-synuc...
Researchers: Caryl E. Sortwell, PhD
Research Grant, 2016
Chronic Effects of Low Frequency Deep Brain Stimulation on Aspiration, Freezing of Gait and Other Axial and Motor Symptoms in Parkinson's Disease
Our recent study (Xie et al., Neurology. 2015;84:415-420) found that 60Hz stimulation, compared to the traditional 130Hz, decreased aspiration frequency and swallowing difficulty, medication refractory freezing of gait (FOG), and other axial symptoms and parkinsonism in those with Parkinson's disease (PD) following bilateral subthalamic nuclei (brain regions associated with PD; STN...
Researchers: Tao Xie, MD, PhD
Therapeutic Pipeline Program, 2016
Cell replacement therapies for Parkinson's disease (PD) propose to replace the lost dopaminergic neurons in the brain. Transplanted fetal dopamine neurons have provided remarkable recovery in some PD patients and can survive and function for decades. More recently, the field has evolved from this innovative but complex fetal dopamine cell transplantation method t...
Researchers: Ole Isacson, MD, PhD
Priority Target Award, 2016
Although pharmacological and surgical treatments are available to manage the symptoms of Parkinson's disease (PD), none yet can slow down or stop the course of the disease. We propose to target a protein (LRRK2) that is altered in PD to modify the disease process.
We seek to elucidate the mechanism by which LRRK2 may be inhibited to stop the progressi...
Researchers: Hao Wu, PhD